Canada markets closed

Small Pharma Inc. (DMT.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.1200-0.0050 (-4.00%)
At close: 03:59PM EST
Full screen
Previous Close0.1250
Open0.1300
Bid0.1150 x N/A
Ask0.1200 x N/A
Day's Range0.1175 - 0.1300
52 Week Range0.0750 - 0.3950
Volume330,390
Avg. Volume228,608
Market Cap38.587M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0710
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.75
  • GlobeNewswire

    Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue

    New United States patents will provide further support for the Company’s proprietary position in a key jurisdiction United States grants will bring the Company’s total to 16 granted patents and over 90 applications pending LONDON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces an update to its intellectua

  • Baystreet

    Stocks in play: Small Pharma Inc.

    Announces that SPL026, intravenous N,N-Dimethyltryptamine, with supportive therapy for the treatment ...

  • GlobeNewswire

    Small Pharma Reports Fiscal Third Quarter 2023 Highlights

    Positive top-line results from Phase IIa trial of SPL026 in Major Depressive Disorder New SPL026 trials underway and screening commenced in the first in-human study of SPL028 LONDON, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, has today published its financial results for the three and nine months ended November 30, 2